Neoantigen-Specific CD8 T Cell Responses in the Peripheral Blood Following PD-L1 Blockade Might Predict Therapy Outcome in Metastatic Urothelial Carcinoma

The authors showed that broadening the number of neoantigen-reactive CD8+ T cell populations between pre-treatment to three weeks post-treatment distinguished patients with controlled disease compared to patients with progressive disease in metastatic urothelial carcinoma treated with PD-L1-blockade.